An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 入组人数
- 60
- 试验地点
- 4
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors
详细描述
An open label multicentric Phase 1 study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors.The study will follow an Accelerated Titration Design (ATD) with 100% dose increments until significant toxicity as described below; followed by standard dose titration with 40% dose increments. Dose and schedule (alternate dosing regimen eg. OD, BID, intermittent) will be determined by the dose escalation outlined in the protocol and considering pharmacokinetics of the study drug determined from earlier cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients having histologically and/or cytologically confirmed non-haematological malignancy that is metastatic or unresectable and for which standard curative/palliative treatment does not exist or is no longer effective or is not tolerated by patient.
- •Patients of either sex, of all races and ethnic groups, and more than 18 years of age.
- •ECOG (Eastern Cooperative Oncology Group) performance status less than
- •Patients with life expectancy of at least 4 months.
- •Patients with measurable or evaluable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.
- •Patients must have adequate organ and marrow function as defined below:
- •Absolute neutrophil count more than equal to 1500/cmm
- •Platelets more than equal 100,000/cmm
- •Total bilirubin within normal limits of the institution.
- •AST/ALT less than equal 2.5 X institutional upper limit of normal (ULN) or less than equal 5 X institutional upper limit of normal (ULN) in the presence of liver metastases
- •Creatinine less than equal 1.5 X institutional upper limit of normal (ULN)
- •Women of childbearing potential and men willing to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilised.
- •Ability to understand and the willingness to provide a written informed consent document.
排除标准
- •Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy or surgery within 4 weeks (3 months for monoclonal antibodies, radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before study drug administration and have not recovered (to < Grade 1) from the toxic effects from any prior therapy.
- •Patients having received any other investigational agents within 4 weeks prior to the date of enrolment and have not recovered completely (to < Grade 1) from the side effects of the earlier investigational agent.
- •Patients with known brain metastases (except for patients who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for two months prior to first dose of study drug.)
- •Patients with a history of myocardial infarction or uncontrolled cardiac dysfunction during the previous 6 months.
- •Patients with diabetes mellitus requiring insulin therapy at screening or patients with clinically significant diabetic complications, such as neuropathy, retinopathy, peripheral vascular disease or nephropathy.
- •Clinically significant medical condition of malabsorption, inflammatory bowel disease, or chronic diarrheal condition that might affect the absorption of the investigational agent.
- •Patients on chronic anticoagulation treatment. Prophylactic anticoagulation with low-molecular heparin is allowed.
- •Patients with inter-current illness including, but not limited to ongoing or clinically significant active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients with a known history of allergic reaction to any other medication considered to be clinically significant by the investigator.
- •Women who are pregnant or nursing.
- •Patients with immune deficiency and at increased risk of lethal infections, for example, known h/o HIV, HBV or HCV.
研究组 & 干预措施
P7170
Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
干预措施: P7170 (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: End of Cycle 1 (i.e. 21 Days)
Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. Toxicities observed in Cycle 1 will be considered for dose limiting toxicity (DLT) and Maximum tolerated dose (MTD)determination.
次要结局
- Number of subject with adverse events(Until disease progression or unacceptable toxicity (expected to be 4-6 months))
- Pharmacokinetic profile(Cmax,Tmax and AUC)(Until disease progression or unacceptable toxicity (expected to be 4-6 months))
- Activity of P7170 based on selected biomarkers(Until disease progression or unacceptable toxicity (expected to be 4-6 months))
- Objective response(Until disease progression or unacceptable toxicity (expected to be 4-6 months))